<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - RIFAMPICIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>RIFAMPICIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Brucellosis in combination with other antibacterials</span>,
                <span class="indication">Legionnaires disease in combination with other antibacterials</span>,
                <span class="indication">Serious staphylococcal infections in combination with other antibacterials</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.6&#8211;1.2 g daily in 2&#8211;4 divided doses.</li>
              <li class="dose child"><strong>For children 1&#8211;11 months</strong><br/>
                5&#8211;10 mg/kg twice daily.</li>
              <li class="dose child"><strong>For children 1&#8211;17 years</strong><br/>
                10 mg/kg twice daily (max. per dose 600 mg).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Endocarditis in combination with other drugs</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.6&#8211;1.2 g daily in 2&#8211;4 divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                600&#8211;900 mg 3 times a week for 6 months (initial and continuation phases).</li>
              <li class="dose child"><strong>For children </strong><br/>
                15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight up to 50 kg)</strong><br/>
                450 mg daily for 6 months (initial and continuation phases).</li>
              <li class="dose adult"><strong>For adults (body-weight 50 kg and above)</strong><br/>
                600 mg daily for 6 months (initial and continuation phases).</li>
              <li class="dose child"><strong>For children (body-weight up to 50 kg)</strong><br/>
                15 mg/kg once daily for 6 months (initial and continuation phases); maximum 450 mg per day.</li>
              <li class="dose child"><strong>For children (body-weight 50 kg and above)</strong><br/>
                15 mg/kg daily for 6 months (initial and continuation phases); maximum 600 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive, in combination with isoniazid</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight up to 50 kg)</strong><br/>
                450 mg daily for 3 months.</li>
              <li class="dose adult"><strong>For adults (body-weight 50 kg and above)</strong><br/>
                600 mg daily for 3 months.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years (body-weight up to 50 kg)</strong><br/>
                15 mg/kg daily for 3 months; maximum 450 mg per day.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years (body-weight 50 kg and above)</strong><br/>
                15 mg/kg daily for 3 months; maximum 600 mg per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years (body-weight up to 50 kg)</strong><br/>
                450 mg daily for 3 months.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years (body-weight 50 kg and above)</strong><br/>
                600 mg daily for 3 months.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive, who are isoniazid-resistant</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 1 month&#8211;11 years (body-weight up to 50 kg)</strong><br/>
                15 mg/kg daily for 6 months; maximum 450 mg per day.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years (body-weight 50 kg and above)</strong><br/>
                15 mg/kg daily for 6 months; maximum 600 mg per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years (body-weight up to 50 kg)</strong><br/>
                450 mg daily for 6 months.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years (body-weight 50 kg and above)</strong><br/>
                600 mg daily for 6 months.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive, who are isoniazid-resistant and under 35 years</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;34 years (body-weight up to 50 kg)</strong><br/>
                450 mg daily for 6 months.</li>
              <li class="dose adult"><strong>For adults 18&#8211;34 years (body-weight 50 kg and above)</strong><br/>
                600 mg daily for 6 months.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of secondary case of <ph outputclass="organism"> <i> <i>Haemophilus influenzae</i> </i> </ph> type b disease</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                600 mg once daily for 4 days.</li>
              <li class="dose child"><strong>For children 1&#8211;2 months</strong><br/>
                10 mg/kg once daily for 4 days.</li>
              <li class="dose child"><strong>For children 3 months&#8211;11 years</strong><br/>
                20 mg/kg once daily (max. per dose 600 mg) for 4 days.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                600 mg once daily for 4 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of secondary case of meningococcal meningitis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                600 mg every 12 hours for 2 days.</li>
              <li class="dose child"><strong>For children 1&#8211;11 months</strong><br/>
                5 mg/kg every 12 hours for 2 days.</li>
              <li class="dose child"><strong>For children 1&#8211;11 years</strong><br/>
                10 mg/kg every 12 hours (max. per dose 600 mg), for 2 days.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                600 mg every 12 hours for 2 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Multibacillary leprosy in combination with dapsone and clofazimine (3-drug regimen)</span>,
                <span class="indication">Paucibacillary leprosy in combination with dapsone (2-drug regimen)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight up to 35 kg)</strong><br/>
                450 mg once a month, supervised administration.</li>
              <li class="dose adult"><strong>For adults (body-weight 35 kg and above)</strong><br/>
                600 mg once a month, supervised administration.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturers advise very high doses teratogenic in <i>animal</i> studies in first trimester; risk of neonatal bleeding may be increased in third trimester.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Avoid or do not exceed 8&#8239;mg/kg daily.</p>
            </section>
            <section class="generalInformation">
              <p>Impaired elimination.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <h3 class="specificity">In children</h3>
              <p>Use with caution if doses above 10&#8239;mg/kg daily.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">In adults</h3>
              <p>Use with caution if dose above 600&#8239;mg daily.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
            <li>jaundice</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Acute renal failure, adrenal insufficiency, alterations of liver function, anorexia, antibiotic-associated colitis, body secretions coloured orange-red, collapse and shock, diarrhoea, disseminated intravascular coagulation, drowsiness, eosinophilia, exfoliative dermatitis, flushing, gastro-intestinal symptoms, haemolytic anaemia, headache, influenza-like symptoms (with chills, fever, dizziness, bone pain), jaundice, leucopenia, menstrual disturbances, muscular weakness, myopathy, nausea, oedema, pemphigoid reactions, psychoses, rashes, respiratory symptoms, saliva coloured orange-red, shortness of breath, Stevens-Johnson syndrome, thrombocytopenic purpura, toxic epidermal necrolysis, urine coloured orange-red, urticaria, vomiting,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> thrombophlebitis reported if infusion used for prolonged period,
              </p>
        
            <section class="advice">
              <p>Discontinue permanently if serious side-effects develop.</p>
            </section>
            <section class="advice">
                <h3>Intermittent therapy</h3>
              <p>Side-effects that mainly occur with intermittent therapy include influenza-like symptoms (with chills, fever, dizziness, bone pain), respiratory symptoms (including shortness of breath), collapse and shock, haemolytic anaemia, thrombocytopenic purpura, disseminated intravascular coagulation, and acute renal failure</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Rifadin</i>
            <tm tmtype="reg"/>), give intermittently <i>in</i> Glucose 5% <i>or</i> Sodium chloride 0.9%; reconstitute with solvent provided then dilute with 500&#8239;mL infusion fluid; give over 2&#8211;3 hours.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>Displacement value may be significant, consult local reconstitution guidelines; reconstitute with solvent provided. May be further diluted with Glucose 5% <i>or</i> Sodium chloride 0.9% to a final concentration of 1.2&#8239;mg/mL. Infuse over 2&#8211;3 hours.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Soft contact lenses</h3>
              <p>Patients or their carers should be advised that rifampicin discolours soft contact lenses.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Hepatic disorders</h3>
              <p>Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Rifampicin for meningococcal prophylaxis</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/rifampicin-for-meningococcal-prophylaxis">www.medicinesforchildren.org.uk/rifampicin-for-meningococcal-prophylaxis</xref>
            </p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Rifampicin for the treatment of tuberculosis</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/rifampicin-for-treatment-of-tuberculosis">www.medicinesforchildren.org.uk/rifampicin-for-treatment-of-tuberculosis</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Discolours soft contact lenses
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
                <h3>Important</h3>
              <p>Effectiveness of hormonal contraceptives is reduced and alternative family planning advice should be offered.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>
            <i>Renal function</i> should be checked before treatment.</p><p>
            <i>Hepatic function</i> should be checked before treatment. If there is no evidence of liver disease (and pre-treatment liver function is normal), further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment. However, liver function should be monitored on prolonged therapy.</p><p>Blood counts should be monitored in patients on prolonged therapy.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">In adults</h3>
              <p>Those with alcohol dependence should have frequent checks of hepatic function, particularly in the first 2 months. Blood counts should also be monitored in these patients.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for use in children for pruritus due to cholestasis.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>If treatment interruption occurs, re-introduce with low dosage and increase gradually.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>In general, doses should be rounded up to facilitate administration of suitable volumes of liquid or an appropriate strength of tablet. Doses may also need to be recalculated to allow for weight gain in younger children.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <p>Flavours of syrup may include raspberry.</p>
            </section>
      </section>








      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

            <section class="contraindications">
              <p>Contra-indicated in patients with rifamycin hypersensitivity.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of RIFAMPICIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,

            <div id="PHP74972"><a href="../medicinalForm/PHP74972.html" data-target="#PHP74972" data-action="load">Capsule</a></div>
            <div id="PHP74996"><a href="../medicinalForm/PHP74996.html" data-target="#PHP74996" data-action="load">Oral suspension</a></div>
            <div id="PHP74985"><a href="../medicinalForm/PHP74985.html" data-target="#PHP74985" data-action="load">Powder and solvent for solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
